Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

The meaning of adherence when behavioral risk patterns vary: obscured use- and method-effectiveness in HIV-prevention trials.

de Bruin M, Viechtbauer W.

PLoS One. 2012;7(8):e44029. doi: 10.1371/journal.pone.0044029. Epub 2012 Aug 31.

3.

Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.

Johnson WD, Diaz RM, Flanders WD, Goodman M, Hill AN, Holtgrave D, Malow R, McClellan WM.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD001230. doi: 10.1002/14651858.CD001230.pub2. Review.

PMID:
18646068
4.

Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.

MacQueen KM, Weaver MA, van Loggerenberg F, Succop S, Majola N, Taylor D, Karim QA, Karim SA.

AIDS Behav. 2014 May;18(5):826-32. doi: 10.1007/s10461-014-0753-8.

5.

Methodological lessons from clinical trials and the future of microbicide research.

van der Straten A, Montgomery ET, Hartmann M, Minnis A.

Curr HIV/AIDS Rep. 2013 Mar;10(1):89-102. doi: 10.1007/s11904-012-0141-9. Review.

PMID:
23184582
6.

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.

Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, Sibeko S, Omar Z, Gengiah TN, Mlotshwa M, Samsunder N, Karim SS.

Trials. 2011 Mar 7;12:67. doi: 10.1186/1745-6215-12-67.

7.

Intravaginal practices and microbicide acceptability in Papua New Guinea: implications for HIV prevention in a moderate-prevalence setting.

Vallely A, Fitzgerald L, Fiya V, Aeno H, Kelly A, Sauk J, Kupul M, Neo J, Millan J, Siba P, Kaldor JM.

BMC Res Notes. 2012 Nov 1;5:613. doi: 10.1186/1756-0500-5-613.

8.

Microbicide clinical trial adherence: insights for introduction.

Woodsong C, MacQueen K, Amico KR, Friedland B, Gafos M, Mansoor L, Tolley E, McCormack S.

J Int AIDS Soc. 2013 Apr 8;16:18505. doi: 10.7448/IAS.16.1.18505. Review.

9.

Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention.

van der Straten A, Van Damme L, Haberer JE, Bangsberg DR.

AIDS. 2012 Apr 24;26(7):F13-9. doi: 10.1097/QAD.0b013e3283522272.

PMID:
22333749
10.

Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand.

Whitehead SJ, McLean C, Chaikummao S, Braunstein S, Utaivoravit W, van de Wijgert JH, Mock PA, Siraprapasiri T, Friedland BA, Kilmarx PH, Markowitz LE.

PLoS One. 2011;6(9):e14831. doi: 10.1371/journal.pone.0014831. Epub 2011 Sep 7.

11.

Efficacy and cost-effectiveness of the first generation of HIV prevention interventions for people with severe and persistent mental illness.

Johnson-Masotti AP, Weinhardt LS, Pinkerton SD, Otto-Salaj LL.

J Ment Health Policy Econ. 2003 Mar;6(1):23-35. Review.

PMID:
14578545
12.

Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis.

Obiero J, Mwethera PG, Hussey GD, Wiysonge CS.

BMC Infect Dis. 2012 Nov 6;12:289. doi: 10.1186/1471-2334-12-289. Review.

13.

Microbicide preference among young women in California.

Holt BY, Morwitz VG, Ngo L, Harrison PF, Whaley KJ, Pettifor A, Nguyen AH.

J Womens Health (Larchmt). 2006 Apr;15(3):281-94.

PMID:
16620187
14.

Interventions to modify sexual risk behaviors for preventing HIV infection in men who have sex with men.

Johnson WD, Hedges LV, Diaz RM.

Cochrane Database Syst Rev. 2003;(1):CD001230. Review. Update in: Cochrane Database Syst Rev. 2008;(3):CD001230.

PMID:
12535405
15.

Changes in sexual risk behavior among participants in a PrEP HIV prevention trial.

Guest G, Shattuck D, Johnson L, Akumatey B, Clarke EE, Chen PL, MacQueen KM.

Sex Transm Dis. 2008 Dec;35(12):1002-8.

PMID:
19051397
16.

A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme.

Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M, Lees S, Stadler J, Crook A, Nunn A, Hayes R, McCormack S.

PLoS One. 2010 Jul 21;5(7):e11600. doi: 10.1371/journal.pone.0011600.

17.

Notes on the frequency of routinely collected and self-reported behavioral data in HIV prevention trials.

Taylor DJ, Lie CC, Weaver MA, Tolley E, Van Damme L, Halpern V, Feldblum P, Ogunsola F, Obunge O, Ramjee G, Alary M, Mirembe F.

AIDS Behav. 2011 Feb;15(2):389-95. doi: 10.1007/s10461-010-9822-9.

PMID:
20957424
18.

Enrollment of adolescents aged 16-17 years old in microbicide trials: an evidence-based approach.

Schenk KD, Friedland BA, Chau M, Stoner M, Plagianos MG, Skoler-Karpoff S, Palanee T, Ahmed K, Rathlagana MJ, Mthembu PN, Ngcozela N.

J Adolesc Health. 2014 Jun;54(6):654-62. doi: 10.1016/j.jadohealth.2014.01.014. Epub 2014 Mar 29.

PMID:
24690188
19.

"We have our protector": misperceptions of protection against HIV among participants in a microbicide efficacy trial.

Mantell JE, Morar NS, Myer L, Ramjee G.

Am J Public Health. 2006 Jun;96(6):1073-7. Epub 2006 May 2.

20.

Adherence and its measurement in phase 2/3 microbicide trials.

Tolley EE, Harrison PF, Goetghebeur E, Morrow K, Pool R, Taylor D, Tillman SN, van der Straten A.

AIDS Behav. 2010 Oct;14(5):1124-36. doi: 10.1007/s10461-009-9635-x. Review.

Items per page

Supplemental Content

Write to the Help Desk